Brii Biosciences

Industry

  • Pharmaceuticals
    • Vaccines
    • Specialty Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies

Other Names/Subsidiaries

  • Brii Biosciences
See more in Biomedtracker

Latest on Brii Biosciences

Scrip

Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE

 
• By Joseph Haas, Dexter Jie Yan, and Jung Won Shin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie To Pay $48m Up Front For Preclin

Scrip

Brii Ups Its Bet On VBI’s Hepatitis B Assets Amid Larger Treatment, Prevention Push

 
• By Alaric DeArment

Brii Biosciences is expanding the scope of its license for an investigational hepatitis B virus (HBV) immunotherapy drug and taking on an HBV vaccine in its more than four-year-old partnership with

Scrip

Creating Best In Class Antivirals In Post-COVID China: Interview with Huahui Health CSO Li Wenhui

 
• By Brian Yang

With severe acute respiratory syndrome (SARS) in 2003 and then COVID-19, China has seen two pandemics originate and spread fast in the country, which has also become known for its large scientific tal

Scrip

Chinese Biotechs Reshuffle Pipeline, Cut Headcount To Stay Afloat

 
• By Dexter Jie Yan

Six Chinese biotechs are reshuffling their research and development programs to conserve funds amid the persistent downturn in the sector, the companies disclosed in their annual results for 2022. Whi